Annual report 2018

Galenica annual report 2018 | 21 Health & Beauty Segment – Products & Brands Business sector Strong OTC sales The systemic pain relief market leader Algifor ® performed very well, clearly exceeding OTC market growth. This was mainly due to the strong flu season at the beginning of 2018 as well as supply constraints of other products in the market. Algifor ® Dolo forte sachets and Algifor ® Dolo forte suspension, a more concentrated liquid formula, were both launched in the Swiss market. Triofan ® maintained its strong market position as the number one nasal decongestant in Switzerland and outperformed in the hay fever market. The iconic Swiss wound treatment brand Merfen ® performed well in 2018, giving Verfora leader- ship in the important wound disinfection consumer health- care category. Several new Perskindol ® products were introduced in 2018, including a thermo hot roll-on and gel, a classic roll-on and a cooling bandage. In addition, a child-friendly and highly effective Anti-Brumm ® Kids formula was launched and well appreciated by parents. Enhanced health and beauty product portfolio Verfora further enhanced its health and beauty product portfolio with both Swiss and international brands. Pharma- cies and drugstores are a trusted source of advice for these products. In the year under review, a new dark spot correc- tor by Lierac was successfully introduced, as well as the product RE30 by Phyto for treating grey hair. The portfolio of the Adler Schüssler mineral salts was enhanced with three unique new “Komplexmittel” products, combining six Schüssler mineral salts in one tablet. In addi- tion, Verfora took over the marketing and national distribu- tion of the successful Oenobiol ® range of nutritional beauty supplements in 2018. The A-Derma skincare line has con- tinued to be a great success since its exclusive Swiss launch in 2016, as have the exclusive Lierac and Phyto brands. “By the third quarter of 2018, Verfora was number one in the Swiss consumer healthcare market for the first time.” 133 Galenica Group 6,580 91.7 Galenica Group CHF 3,165.0 million Companies – G-Pharma Ltd. – Verfora Ltd. Number of employees Net sales in million CHF Products & Brands